Agios Pharmaceuticals
AGIO
Market cap $2.58B

45.41 USD

-0.25

0.55%

Updated Oct 22, 10:45 AM EDT

1 day

-0.55%

5 days

6.02%

1 month

-0.76%

3 months

-4.90%

6 months

50.31%

Year to date

98.90%

1 year

116.65%

5 years

39.64%

About: Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Employees: 386

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

69% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 29

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

35% more capital invested

Capital invested by funds: $1.78B [Q1] → $2.41B (+$629M) [Q2]

11% more funds holding

Funds holding: 183 [Q1] → 203 (+20) [Q2]

6% more call options, than puts

Call options by funds: $12.4M | Put options by funds: $11.8M

9.96% less ownership

Funds ownership: 108.4% [Q1] → 98.44% (-9.96%) [Q2]

38% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 80

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$51

12%

upside

Avg. target

$54

18%

upside

High target

$56

23%

upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

Scotiabank Greg Harrison 70% 1-year accuracy 14 / 20 met price target	12%upside $51	Sector Outperform Initiated	16 Oct 2024
Raymond James Danielle Brill 82% 1-year accuracy 14 / 17 met price target	12%upside $51	Outperform Reinstated	10 Oct 2024
Leerink Partners Andrew Berens 67% 1-year accuracy 2 / 3 met price target	23%upside $56	Market Perform Downgraded	27 Sept 2024
RBC Capital Gregory Renza 66% 1-year accuracy 41 / 62 met price target	21%upside $55	Outperform Reiterated	19 Sept 2024
RBC Capital Gregory Renza 66% 1-year accuracy 41 / 62 met price target	21%upside $55	Outperform Maintained	2 Aug 2024

See Analyst Rankings

Financial journalist opinion

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 31, 2024, at 8:00 a.m. ET to report its third quarter 2024 financial results and business highlights.

Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

Zacks Investment Research

FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer

The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.

FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

CAMBRIDGE, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's novel pyruvate kinase (PK) activator tebapivat (AG-946) for the treatment of myelodysplastic syndromes (MDS).

Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company is scheduled to present at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:20 a.m.

Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

Agios' Pyrukynd is FDA-approved for pyruvate kinase deficiency but generated modest sales of $8.6 million in Q2 2024. Mitapivat shows promise in treating SCD and thalassemia, with ongoing Phase 3 trials showing positive results for hemoglobin improvement. Expanding Pyrukynd's label to include pediatric and thalassemia indications is crucial, with regulatory filings expected by 2025.

Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

– Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments Increase Agios' Pro-Forma Cash Position as of June 30, 2024, to $1.7 Billion – – Strong Cash Position to Enable Agios to Prepare for Potential PYRUKYND® (Mitapivat) Launches in Thalassemia in 2025 and Sickle Cell Disease in 2026 and Drive Pipeline Progress – CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the Company will receive a total of $1.1 billion in milestone payments following the U.S. Food and Drug Administration (FDA) approval of vorasidenib for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery, including biopsy, sub-total resection or gross total resection.

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Zacks Investment Research

AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal

Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency.

AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

On Thursday, Agios Pharmaceuticals Inc AGIO released topline results from the global Phase 3 ACTIVATE-KidsT study of mitapivat in children aged 1 to

Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides

Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Transcript

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2024 Results Conference Call August 1, 2024 8:00 AM ET Company Participants Chris Taylor - Vice President, Investor Relations and Corporate Communications Brian Goff - Chief Executive Officer Sarah Gheuens - Chief Medical Officer and Head, R&D Tsveta Milanova - Chief Commercial Officer Cecilia Jones - Chief Financial Officer Conference Call Participants Eric Schmidt - Cantor Christopher Raymond - Piper Sandler Gregory Renza - RBC Capital Markets Divya Rao - TD Cowen Tess Romero - JP Morgan Alec Stranahan - Bank of America Operator Good morning, and welcome to Agios' Second Quarter 2024 Conference Call. [Operator Instructions].

Agios Pharmaceuticals, Inc. (AGIO) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.69 per share versus the Zacks Consensus Estimate of a loss of $1.58. This compares to loss of $1.51 per share a year ago.

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates

See News Rankings

Charts implemented using Lightweight Charts™